Adam Feuerstein

Adam Feuerstein is an American journalist and columnist covering the biotechnology sector.

Education

Adam Feuerstein completed a bachelor's degree in political science at Emory University.[1]

Career

Feuerstein covered business, technology, and commercial real estate for the San Francisco Business Times and the Atlanta Business Chronicle as an assistant managing editor.[1][2] He later wrote about business software for Upside.com. In March 2001, he joined TheStreet.com. From 2005 to 2006 he worked as a research analyst for a hedge fund before returning to TheStreet. He resigned in May 2017. Feuerstein accepted a position as a national biotechnology columnist at STAT in June 2017.[1]

Feuerstein is known for his style of reporting and his tweets to his large Twitter following.[3][4] He often shares "unabashed" views on Biotech stock and the Food and Drug Administration.[5]

Criticism

Fauerstein has been accused of publishing false or embellished stories in an effort to claim relevance as a journalist and bully companies, most recently in a series of attack stories on a company involved in testing the treatment Leronlimab on severe and critical COVID-19 patients. [6]

Feuerstein is sometimes the subject of criticism from different parties in the biotechnology sector.[7]

References
  1. Roush, Chris (May 30, 2017). "TheStreet's Feuerstein leaving for STAT". Talking Biz News. Retrieved 2018-11-23.
  2. "Adam Feuerstein Preps for Move to STAT". Cision. June 1, 2017. Retrieved 2018-11-23.
  3. Robbins, Rebecca (May 2, 2016). "Is Adam Feuerstein the most feared man in biotech?". STAT. Retrieved 2018-11-23.
  4. Valleskey, Brianna (November 14, 2014). "How Adam Feuerstein Follows The Biotech Sector". Benzinga. Retrieved 2018-11-23 – via Yahoo.
  5. Schifrin, Matthew (2010-10-01). The Warren Buffetts Next Door: The World's Greatest Investors You've Never Heard Of and What You Can Learn From Them. John Wiley & Sons. p. 88. ISBN 9780470915301.
  6. Growth, Emerging (May 8, 2020). "STAT Reporter Triples Down on CytoDyn (OTCQB: CYDY) Rhetoric with Failed Cyber Bullying Tactics". Emerging Growth. Retrieved 2020-05-08.
  7. Pearlstein, Steven (September 27, 2014). "Northwest Biotherapeutics stock woes highlight the harm of short sales". The Washington Post. Retrieved 2018-11-23.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.